WO2011104412A3 - Compuestos para el tratamiento de alzheimer - Google Patents

Compuestos para el tratamiento de alzheimer Download PDF

Info

Publication number
WO2011104412A3
WO2011104412A3 PCT/ES2011/070120 ES2011070120W WO2011104412A3 WO 2011104412 A3 WO2011104412 A3 WO 2011104412A3 ES 2011070120 W ES2011070120 W ES 2011070120W WO 2011104412 A3 WO2011104412 A3 WO 2011104412A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compounds
amyloid deposits
treating alzheimer
formation
Prior art date
Application number
PCT/ES2011/070120
Other languages
English (en)
French (fr)
Other versions
WO2011104412A2 (es
Inventor
Carlos Matute Almau
José Luis ZUGAZA GURRUCHAGA
Original Assignee
Universidad Del País Vasco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Del País Vasco filed Critical Universidad Del País Vasco
Publication of WO2011104412A2 publication Critical patent/WO2011104412A2/es
Publication of WO2011104412A3 publication Critical patent/WO2011104412A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos inhibidores de PKCs pueden ser utilizados para el tratamiento de enfermedades asociadas a la formación de depósitos amiloideos, entre las que se encuentra la enfermedad de Alzheimer. Los niveles de activación de dichas PKCs en una célula tratada con una proteína amiloidea pueden ser utilizados para identificar compuestos capaces de inhibir la muerte celular inducida por depósitos amiloideos potencialmente útiles en el tratamiento de enfermedades asociadas a la formación de depósitos amiloideos.
PCT/ES2011/070120 2010-02-25 2011-02-24 Compuestos para el tratamiento de alzheimer WO2011104412A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201030267 2010-02-25
ES201030267A ES2385157B1 (es) 2010-02-25 2010-02-25 Compuestos para el tratamiento de alzheimer.

Publications (2)

Publication Number Publication Date
WO2011104412A2 WO2011104412A2 (es) 2011-09-01
WO2011104412A3 true WO2011104412A3 (es) 2011-11-17

Family

ID=44507296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070120 WO2011104412A2 (es) 2010-02-25 2011-02-24 Compuestos para el tratamiento de alzheimer

Country Status (2)

Country Link
ES (1) ES2385157B1 (es)
WO (1) WO2011104412A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT515336A1 (de) * 2014-02-03 2015-08-15 Roth Hermann Dr Vermeidung oxidativer Prozesse und oxidativem Stress
US20180311236A1 (en) * 2015-10-28 2018-11-01 Ab Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
WO2022261752A1 (en) * 2021-06-14 2022-12-22 Alex Parker Compounds and methods for the treatment of neurodegenerative disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719175A (en) * 1993-12-07 1998-02-17 Eli Lilly And Company Protein kinase C inhibitors
ES2162843T3 (es) * 1993-12-07 2002-01-16 Lilly Co Eli Inhibidores de la proteina quinasa c.
ES2241316T3 (es) * 1998-08-26 2005-10-16 Cephalon, Inc. Modulacion de proteinas quinasa de linaje multiple.
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US7632819B1 (en) * 2004-10-29 2009-12-15 Iowa State University Research Foundation, Inc. Methods and compositions for inhibiting PKC delta cleavage for treatment and prevention of neurodegeneration and apoptosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719175A (en) * 1993-12-07 1998-02-17 Eli Lilly And Company Protein kinase C inhibitors
ES2162843T3 (es) * 1993-12-07 2002-01-16 Lilly Co Eli Inhibidores de la proteina quinasa c.
ES2241316T3 (es) * 1998-08-26 2005-10-16 Cephalon, Inc. Modulacion de proteinas quinasa de linaje multiple.
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US7632819B1 (en) * 2004-10-29 2009-12-15 Iowa State University Research Foundation, Inc. Methods and compositions for inhibiting PKC delta cleavage for treatment and prevention of neurodegeneration and apoptosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUNY G. D.: "Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions", CURRENT PHARMACEUTICAL DESIGN, vol. 15, 2009, pages 3919 - 3939 *
DASTMALCHI K. ET AL.: "Plants as potential sources for drug development against Alzheimer's Disease", INTERNATIONAL JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES, vol. 1, no. 2, 2007, pages 83 - 104 *
GSCHWENDT M. ET AL.: "Rottlerin, a novel protein kinase inhibitor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 1, 28 February 1994 (1994-02-28), pages 93 - 98 *
MARTINEZ A. ET AL.: "GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?", JOURNAL OF ALZHEIMER DISEASE, vol. 15, 2008, pages 181 - 191 *
MEIJER L. ET AL.: "Pharmacological inhibitors of glycogen synthase kinase 3", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 25, no. 9, 29 July 2004 (2004-07-29) *

Also Published As

Publication number Publication date
WO2011104412A2 (es) 2011-09-01
ES2385157A1 (es) 2012-07-19
ES2385157B1 (es) 2013-07-08

Similar Documents

Publication Publication Date Title
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
WO2012062925A3 (en) Compounds and methods for treating pain
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
BR112015020466A2 (pt) inibidores de cdc7
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201691354A1 (ru) Терапевтические ингибирующие соединения
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
UA114090C2 (uk) Сполуки, що інгібують металоферменти
WO2013188813A3 (en) Novel therapeutics for brain cancer
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
EA201491221A1 (ru) Новые молекулы, ингибирующие jnk, для лечения различных болезней
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
MY156243A (en) Treatment for diabetes in patients inappropriate for metformin therapy
WO2011083150A3 (en) Obesity small molecules
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
WO2010059004A3 (ko) 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2012044090A3 (ko) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
WO2013098416A3 (fr) Composes anti-douleur
WO2011082245A3 (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11746904

Country of ref document: EP

Kind code of ref document: A2